Clinical Trial Update: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) [Phase 1]

View source ↗

Summary

Phase 1 study update (FORTIFY) of NG-350A in combination with pembrolizumab for metastatic or advanced epithelial tumors has completed enrollment; no efficacy r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• NG-350A

Snippet

Sponsor: Akamis Bio | Conditions: Epithelial Tumor, Metastatic Cancer | Phase 1 | Status: COMPLETED